Allogene Therapeutics, Inc. (ALLO) Stock Price & Analysis
Allogene Therapeutics, Inc. (ALLO) fell 4.40% to USD 1.74 as of July 25, 2026 at 03:56 UTC, according to Nexqual real-time market data.
ALLO last closed at USD 1.82; the session ranged USD 1.74–1.84 on volume of 4,843,692 shares. Market capitalization is $600.57M, with a 52-week range of USD 0.98–4.46 (NMS). Source: Nexqual, July 25, 2026 at 03:56 UTC.
Key Statistics (as of July 25, 2026 at 03:56 UTC)
| Price | USD 1.74 |
|---|---|
| Change | ▼ 4.40% (down) |
| Previous Close | USD 1.82 |
| Open | USD 1.83 |
| Day Range | USD 1.74 – 1.84 |
| 52-Week Range | USD 0.98 – 4.46 |
| Volume | 4,843,692 shares |
| Market Cap | $600.57M |
| Exchange | NMS |
Technical Analysis (ALLO)
Nexqual's technical model rates ALLO "SELL" based on 1 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 03:56 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 37.57 (neutral) |
| vs SMA50 | Below (USD 2) |
| MACD | -0.07 (negative) |
Analyst Ratings (ALLO)
Wall Street analysts rate ALLO "Strong Buy" based on 9 analysts, with a mean price target of USD 9 (range USD 4–14), per Nexqual as of July 25, 2026 at 03:56 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 9 |
| Mean Target | USD 9 |
| High Target | USD 14 |
| Low Target | USD 4 |
| Buy / Hold / Sell | 11 / 1 / 0 |
Earnings (ALLO)
| Next Earnings Date | 2026-08-12 |
|---|---|
| EPS Estimate | USD -0.15 |
| Revenue Estimate | $2,220 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.18 vs est -0.18 ▲ beat |
| 2025-12-31 | USD -0.17 vs est -0.22 ▲ beat |
| 2025-09-30 | USD -0.19 vs est -0.23 ▲ beat |
| 2025-06-30 | USD -0.22 vs est -0.27 ▲ beat |
Source: Nexqual, July 25, 2026 at 03:56 UTC.
Financials & Fundamentals (ALLO)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -52.32% |
| Debt / Equity | 29.06 |
| Current Ratio | 9.65 |
| Total Cash | $266.89M |
| Total Debt | $81.05M |
| Free Cash Flow | $-69.94M |
Source: Nexqual, July 25, 2026 at 03:56 UTC.
Financial Health Score (ALLO)
Nexqual rates Allogene Therapeutics, Inc.'s overall financial health "Weak" across five dimensions, as of July 25, 2026 at 03:56 UTC.
| Growth | Critical — Revenue -100% YoY (annual), sharp decline |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $267M cash vs $81M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$109M |
| Efficiency | Critical — ROE -52%, ROA -26.0% |
Ownership (ALLO)
| Insider Ownership | +11.04% |
|---|---|
| Institutional Ownership | +53.93% |
| Shares Outstanding | 345.15M |
| Float | 270.63M |
| Short % of Float | +20.32% |
Source: Nexqual, July 25, 2026 at 03:56 UTC.
Leadership (ALLO)
Allogene Therapeutics, Inc. is led by Zachary J. Roberts (age 47), President, CEO & Director, per Nexqual as of July 25, 2026 at 03:56 UTC.
| President, CEO & Director | Zachary J. Roberts (age 47) |
|---|---|
| Co-Founder & Executive Chairman | Arie S. Belldegrun F.A.C.S. (age 76) |
| Co-Founder & Director | Joshua A. Kazam (age 48) |
| Co-Founder & Director | David D. Chang (age 65) |
| Executive VP & CFO | Geoffrey M. Parker (age 60) |
Major Backers & Investors (ALLO)
Notable institutional backers of Allogene Therapeutics, Inc. include Pfizer Inc, TPG GP A, LLC, Fidelity, according to Nexqual as of July 25, 2026 at 03:56 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Pfizer Inc | 6.38% |
| TPG GP A, LLC | 5.42% |
| Fidelity | 2.77% |
| Primecap Management Company | 2.43% |
| Citadel | 1.97% |
| Price (T.Rowe) Associates Inc | 1.56% |
| Two Sigma Investments, LP | 1.56% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 7.1% |
| State Street | 6.02% |
| Vanguard Group | 5.52% |
Source: Nexqual, July 25, 2026 at 03:56 UTC.
From Allogene Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-12)
Key Strengths & Strategy (as disclosed to the SEC)
- Multiple autologous anti-CD19 CAR T therapies have shown promising results and have been approved by the FDA as therapies in multiple blood cancers, including relapsed/refractory (R/R) LBCL, as further described below under "—Competition".
- This practice encompasses a wide range of indications and modalities, including those classified as Advanced Therapy Medicinal Products by the EMA.
- We believe a critical component to our success will be to leverage and expand our proprietary manufacturing know-how, expertise and capacity.
- Product Pipeline and Development Strategy Using our proprietary allogeneic CAR T cell platform, we are researching and developing multiple product candidates for the treatment of blood cancers, solid tumors and autoimmune diseases.
Partnerships
- In February 2025, we entered into an Amended and Restated Strategic Collaboration Agreement with Foresight Diagnostics which expands our collaboration to enable the development of Foresight Diagnostics' CLARITY TM MRD assay as a companion diagnostic in the EU, UK, Canada and Australia in support of Allogene's clinical development of cema-cel.
- On May 10, 2024, we entered into an Amendment and Settlement Agreement (the Servier Amendment) with Servier which restructures our relationship under the Servier Agreement.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ATRA | Atara Biotherapeutics, Inc. | USD 7.9 | ▼ 2.77% |
| FATE | Fate Therapeutics, Inc. | USD 2.41 | ▼ 6.59% |
| AUTL | Autolus Therapeutics plc | USD 1.45 | ▲ 0.69% |
| ARVN | Arvinas, Inc. | USD 8.03 | ▼ 2.78% |
| DNLI | Denali Therapeutics Inc. | USD 23.11 | ▼ 2.24% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 03:56 UTC. This page is informational and not investment advice.